Drug Topics e-News:
Having trouble viewing this email? View in a browser.
|
You are subscribed to %%list.name%% as %%emailaddr%%. Unsubscribe.
|
to Drug Topics e-News
|
|
|
|
 |
 |
| Newest: Dietary supplements and patient counseling |
| For pharmacists, from Drug Topics: Continuing education for pharmacists and pharmacy technicians. Go to CE site here |
|
|
|
|
Survey
This month we would like to know...
In your practice setting, has the process for Risk Evaluation and Mitigation Strategies (REMS) implementation been automated?
• Yes, we are using an automated system.
• No, we are not yet using an automated system.
• No, but we plan to use an automated system in the next 6 months.
• No, but we plan to use an automated system in the next 12 months.
|
|
|
A daily dose of opioids for nonmalignant pain is strongly associated with opioid-related mortality, and doses of 200 mg or more of morphine or equivalent are associated with a particularly high risk, according to a recent study published in Archives of Internal Medicine. Read full article. |
 |
|
|
To confirm your e-newsletter subscription, click here.
To ensure future delivery of email newsletters from
Drug Topics, please take a moment to confirm your subscription by clicking here.
Thank you,
Drug Topics Staff
|
 |
A discussion generated by
Drug Topics’ readers, editorial staff, and advisory board
James Rawlings is a senior pharmacist at a hospital in central Indiana. |
Dear Drugmonkey
Read full article.
|
|
FDA approved the use of meningococcal (A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccine (Menactra, Sanofi Pasteur) in children aged as young as 9 months for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Read full article.
|
|
Hemoglobin A1c levels below 6% are associated with a small but significant increased risk of mortality in elderly patients, according to a retrospective cohort study published online in Diabetes Care. Read full article.
|
The American Pain Foundation recently released a new medication safety module on acetaminophen and nonsteroidal anti-inflammatory drugs as part of its PainSAFE initiative. Read full article. |
|
FDA has approved abiraterone acetate (Zytiga, Centocor Ortho Biotech), an oral, once-daily medication for use in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel. Read full article. |
|
FDA approved linagliptin (Tradjenta, Boehringer Ingelheim and Eli Lilly) tablets, used with diet and exercise, to improve blood glucose control in adults with type 2 diabetes. Read full article. |
|
In 2013, NACDS will unify its current Marketplace Conference, Pharmacy & Technology Conference, and Supply Chain & Logistics Conference into one new event, the NACDS Total Store Expo. Read full article. |
 |
Meetings and Events
May 15-19, 2011 NCPDP 2011 Annual Technology & Business Conference
Phoenix
Contact:
Jenny Powers
480-477-1000 ext. 143
jpowers@ncpdp.org
May 17-19, 2011 ASCP Spring Conference + Exhibition (formerly known as the ASCP Midyear Conference)
Las Vegas
Contact:
Alexandria, VA 22314
Phone: 703-739-1300 or 800-355-2727
Fax: 703-739-1321 or 800-220-1321
info@ascp.com
May 23-25, 2011 NCPA Legislative Conference
Washington, DC
Contact:
100 Daingerfield Road
Alexandria, VA 22314
800-544-7447
June 1-2, 2011 PQA Annual Meeting
Washington, DC
Contact:
Karen Peterson
9687 South Run Oaks Drive
Fairfax Station, VA 22039
Fax: 703-690-1756
kpeterson@pqaalliance.org
June 2-3 PQA/URAC Medication Adherence Summit
Washington, DC
Contact:
Jackie Green
1220 L Street NW, Suite 400
Washington, DC 20005
703-927-1599
jgreen@pqaalliance.org
|
|
|
|
| Contact Us |
Contact a Drug Topics editor Click Here
Contact a Drug Topics sales representative Click Here
Learn about direct mail, reprints and classifieds in Drug Topics Click Here |
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
